As automation replaces repetitive tasks and intelligent systems become more advanced, the demand for new types of skills is rising dramatically, ...

Artificial intelligence is rapidly transforming the landscape of programming education . Tools can now generate syntactically correct code within seconds .

Overview: Learning one programming language and core concepts builds the base for solving coding interview problems effectively.Strong knowledge of data structu ...

Using the right study materials can help strengthen the skills required to crack technical interviews in 2026. They aid in strengthening problem-solving skills, ...

Rock Springs Capital Management sold 202,918 shares of GPCR in the fourth quarter; the estimated transaction value was $8.29 million based on quarterly average pricing. Despite the sale, the ...

Feb 10 (Reuters) - Microsoft (MSFT.O), opens new tab is exploring using superconducting power lines in its data centers, which could potentially accelerate its massive U.S. build-out of the server ...

Federal immigration agents detain a man during an operation by Immigration and Customs Enforcement (ICE) and Border Patrol in St. Paul, Minnesota, on Jan. 27, 2026. (Photo by Octavio JONES / AFP via ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Abstract: This paper explores the potential of AI chatbots in enhancing the teaching of data structures and algorithms (DSA) in computer science education. We present our experience using AI chatbots ...

Geoff’s column hunts for how tech can make your life better — and advocates for you when tech lets you down. Got a question or topic to investigate? [email protected] and geoffreyfowler.88 ...

The last time I wrote an article on Structure Therapeutics Inc. (GPCR) it was in a Seeking Alpha article entitled "Structure Therapeutics: Potential To Have Best-In-class GLP-1 Agonist For Obesity ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...